Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) shares traded up 4.8% on Thursday . The company traded as high as $3.40 and last traded at $3.29, with a volume of 388,560 shares traded. The stock had previously closed at $3.14.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 25th. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 9th. HC Wainwright initiated coverage on shares of Anthera Pharmaceuticals in a research report on Friday, July 8th. They set a “buy” rating and a $10.00 price objective for the company. Finally, FBR & Co reaffirmed a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $9.58.

The firm’s market capitalization is $133.21 million. The stock has a 50-day moving average of $3.18 and a 200-day moving average of $3.41.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. On average, equities research analysts expect that Anthera Pharmaceuticals Inc. will post ($1.26) EPS for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.